NASDAQ : TRDA
Entrada Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.4 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 158.65M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 184.25M |
| Enterprise Value | 9.79M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 36.06M |
| Shares Outstanding | 36.06M |
| Shares Change (YoY) | +1.93% |
| Shares Change (QoQ) | +0.92% |
| Owned by Insiders (%) | 1.79% |
| Owned by Institutions (%) | 52.63% |
| Float | 22.67M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 35.47 |
| Forward PS | 4.78 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.89 |
| Quick Ratio | 10.52 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -54.09% |
| Return on Assets (ROA) | -29.20% |
| Return on Invested Capital (ROIC) | -280.08% |
| Return on Capital Employed (ROCE) | -62.93% |
| Weighted Average Cost of Capital (WACC) | 2.28% |
| Revenue Per Employee | $30,829 |
| Profits Per Employee | -$1.09M |
| Employee Count | 152 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 819,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.24 |
| 52-Week Price Change | -26.47% |
| 50-Day Moving Average | 6.00 |
| 200-Day Moving Average | 8.74 |
| Relative Strength Index (RSI) | 49.07 |
| Average Volume (20 Days) | 405,947 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.27M |
| Short Previous Month | 2.99M |
| Short % of Shares Out | 9.07% |
| Short % of Float | 14.43% |
| Short Ratio (days to cover) | 9.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.69M |
| Gross Profit | -134.36M |
| Operating Income | -174.63M |
| Pretax Income | -164.96M |
| Net Income | -165.78M |
| EBITDA | -170.86M |
| EBIT | -174.63M |
| Loss Per Share | -$3.97 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 223.01M |
| Total Debt | 48.54M |
| Net Cash | 174.46M |
| Net Cash Per Share | $4.84 |
| Equity (Book Value) | 233.41M |
| Book Value Per Share | 6.47 |
| Working Capital | 211.33M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -134.67M |
| Capital Expenditures | 323,000 |
| Depreciation & Amortization | 3.76M |
| Net Borrowing | n/a |
| Free Cash Flow | -134.35M |
| FCF Per Share | -$3.73 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -3,726.53% |
| Pretax Margin | -3,520.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.93% |
| Shareholder Yield | -1.93% |
| Earnings Yield | -77.64% |
| FCF Yield | -80.83% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $19.00 |
| Price Target Difference | 271.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | -7.85% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.16 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |